PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27461468-5	2016	Under the assumption that, if a gene mediates EGCG"s cancer inhibition, its expression level change caused by EGCG should be opposite to what occurred in the carcinogenesis, we identified Myb and Peg3 as the primary putative genes involved in the cancer inhibitory activity.	epigallocatechin gallate	46-50	paternally expressed 3	Mus musculus	196-200	
27461468-5	2016	Under the assumption that, if a gene mediates EGCG"s cancer inhibition, its expression level change caused by EGCG should be opposite to what occurred in the carcinogenesis, we identified Myb and Peg3 as the primary putative genes involved in the cancer inhibitory activity.	epigallocatechin gallate	110-114	paternally expressed 3	Mus musculus	196-200	
27461468-7	2016	CONCLUSIONS: Although the actions of EGCG involve multiple targets/pathways, further analysis by mining the existing genomic datasets revealed that the upregulations of Myb and Peg3 are likely the key anti-cancer events of EGCG in vivo.	epigallocatechin gallate	37-41	paternally expressed 3	Mus musculus	177-181	
27461468-7	2016	CONCLUSIONS: Although the actions of EGCG involve multiple targets/pathways, further analysis by mining the existing genomic datasets revealed that the upregulations of Myb and Peg3 are likely the key anti-cancer events of EGCG in vivo.	epigallocatechin gallate	223-227	paternally expressed 3	Mus musculus	177-181